Highly efficacious factor Xa inhibitors containing α-substituted phenylcycloalkyl P4 moieties

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 2, 2009, Pages 462-468

  Qiao, Jennifer X ^a   King, Sarah R ^a   He, Kan ^a   Wong, Pancras C ^a   Rendina, Alan R ^a   Luettgen, Joseph M ^a   Xin, Baomin ^a   Knabb, Robert M ^a   Wexler, Ruth R ^a   Lam, Patrick Y S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Substituted phenylcyclopropyls; Factor Xa inhibitors; Pharmacokinetic; Rabbit arterio venous shunt; SAR

Indexed keywords

APIXABAN; BENZENE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYCLOALKANE DERIVATIVE; RAZAXABAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; NONHUMAN; PERMEABILITY; RABBIT; SHUNT THROMBOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CACO-2 CELLS; FACTOR XA; HUMANS; PYRIDONES; RABBITS; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 57749111770     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.049     Document Type: Article

References (28)

1. For recent review papers of FXa inhibitors, see:. Quan M., and Smallheer J. Curr. Opin. Drug Discov. Dev. 7 (2004) 460
2. Walenga J.M., Jeske W.P., Hoppensteadt D., and Fareed J. Curr. Opin. Investig. Drugs 4 (2003) 272
3. Gould W.R., and Leadley R. J. Curr. Pharm. Des. 9 (2003) 2337
4. Quan M.L., and Wexler R.R. Curr. Topics Med. Chem. 1 (2001) 137
5. Zhu B., and Scarborough R.M. Ann. Rep. Med. Chem. 35 (2000) 83
6. Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., and Deitchman D. Blood 102 (2003) 11
7. Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.-H., Reinemer P., Perzborn E., and Roehrig S. J. Med. Chem. 48 (2005) 5900
8. Eriksson B.L., Borris L., Dahl O.E., Haas S., Huisman M.V., and Kakkar A.K.J. Thromb. Haemost. 4 (2006) 121
9. Hampton T. JAMA 295 (2006) 743
10. Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., and Deitchman D. Thromb. Haemost. 5 (2007) 2368
11. Wong P.C., Crain E.J., Watson C.A., Xin B., Wexler R.R., Lam P.S.Y., Pinto D.J., Luettgen J.M., and Knabb R.M. J. Thromb. Haemost. 6 (2008) 820-829
12. Turpie A.G.G. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1238 and references therein
13. Quan M.L., Lam P.Y.S., Han Q., Pinto D.J.P., He M.Y., Li R., Ellis C.D., Clark C.G., Teleha C.A., Sun J.-H., Alexander R.S., Bai S., Luettgen J.M., Knabb R.M., Wong P.C., and Wexler R.R. J. Med. Chem. 48 (2005) 1729
14. Wong P.C., Crain E.J., Watson C.A., Wexler R.R., Lam P.Y.S., Quan M., and Knabb R.M. J. Thromb. Thrombol. 24 (2007) 43
15. Pinto D.J.P., Orwat M.J., Koch S., Rossi K.A., Alexander R.S., Smallwood A., Wong P.C., Rendina R.A., Luettgen J.M., Knabb R.M., He K., Xin B., Wexler R.R., and Lam P.Y.S. J. Med. Chem. 50 (2007) 5339
16. Qiao J.X., Cheney D.L., Alexander R.S., King S.R., Rendina A.R., Luettgen J.M., Knabb R.M., Wexler R.R., and Lam P.Y.S. Bioorg. Med. Chem. Lett. 18 (2008) 4118
17. Knabb R.M., Kettner C.A., Timmermans P.B.M.W.M., and Reilly T.M. Thromb. Haemost. 67 (1992) 56
18. Kettner C.A., Mersinger L.J., and Knabb R.M. J. Biol. Chem. 265 (1990) 18289
19. Hilgers A.R., Conradi R.A., and Burton S. Pharm. Res. 7 (1990) 902-910
20. Qiao J.X., Cheng X., Smallheer J.M., Galemmo R.A., Spencer D., Pinto D.J.P., Cheney D.L., He K., Wong P.C., Luettgen J.M., Knabb R.M., Wexler R.R., and Lam P.Y.S. Bioorg. Med. Chem. Lett. 17 (2007) 1432
21. Wong P.C., Quan M.L., Crain E.J., Watson C.A., Wexler R.R., and Knabb R.M. J. Pharmacol. Exp. Ther. 292 (2000) 351
22. Wong P.C., Crain E.J., Knabb R.M., Meade R.P., Quan M.L., Watson C.A., Wexler R.R., Wright M.R., and Slee A.M. J. Pharmacol. Exp. Ther. 295 (2000) 212
23. Wong P.C., Watson C.A., Crain E.J., Zaspel A.M., Luettgen J.M., Bai S.M., Lam P.Y., Quan M.L., Wexler R.R., and Knabb R.M. Blood 102 (2003) 813a
24. Compounds 2d, 3b, 3d and others in this series also had favorable, rapid rates of association (on-rates) comparable to razaxaban, apixaban, and other FXa inhibitors, near the diffusion controlled limit. Rapid onset of inhibition is preferred and observed for coagulation.
25. Elg M., Gustafsson D., and Denium J. J. Thromb. Haemost. 78 (1997) 1286
26. Rezaie A.R. Thromb. Haemost. 89 (2003) 112
27. Gould W.R., Cladera E., Harris M.S., Zhang E., Narasimhan L., Thorn J.M., and Leadley R.L. Biochemistry 44 (2005) 9280
28. Pinto D.J.P., Orwat M.J., Quan M.L., Han Q., Galemmo R.A., Amparo E., Wells B., Smallwood A., Wong P.C., Luettgen J.M., Rendina A.R., Knabb R.M., Mersinger L., Kettner C., Bai S., He K., Wexler R.R., and Lam P.Y.S. Bioorg. Med. Chem. Lett. 16 (2006) 4141